{"nctId":"NCT01281839","briefTitle":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","startDateStruct":{"date":"2011-02"},"conditions":["Hepatitis C"],"count":394,"armGroups":[{"label":"TMC435","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Peginterferon alpha-2a (PegIFN alpha-2a)","Drug: Ribavirin (RBV)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Peginterferon alpha-2a (PegIFN alpha-2a)","Drug: Ribavirin (RBV)"]}],"interventions":[{"name":"TMC435","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Peginterferon alpha-2a (PegIFN alpha-2a)","otherNames":["Pegasys"]},{"name":"Ribavirin (RBV)","otherNames":["Copegus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genotype 1 hepatitis C infection (confirmed at screening)\n* Have previously received peginterferon-based therapy for at least 24 weeks with documented HCV RNA at last measurement and relapsed within 1 year of last taking medication\n* Liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection\n* Must agree to use 2 forms of effective contraception throughout study (both males and females)\n\nExclusion Criteria:\n\n* Infection with HIV or non-genotype 1 hepatitis C\n* Liver disease not related to hepatitic C infection\n* Hepatic decompensation\n* Significant laboratory abnormalities or other active diseases\n* Pregnant or planning to become pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","description":"The table below shows the percentage of participants in each treatment group who achieved a SVR12, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid 12 weeks after planned end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)","description":"The table below shows the percentage of participants in each treatment group who achieved a SVRW72, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid levels at end of treatment (EOT) and at Week 72.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"33.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)","description":"The table below shows the percentage of participants in each treatment group who achieved a SVR24, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid levels 24 weeks after planned end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"33.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)","description":"The table below shows the percentage of participants in each treatment group who achieved a SVR4, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid levels 4 weeks after planned end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"48.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)","description":"The table below shows change from baseline in log10 HCV RNA levels.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.537","spread":"0.042"},{"groupId":"OG001","value":"-1.039","spread":"0.072"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.535","spread":"0.040"},{"groupId":"OG001","value":"-1.099","spread":"0.073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.295","spread":"0.049"},{"groupId":"OG001","value":"-2.638","spread":"0.125"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.404","spread":"0.049"},{"groupId":"OG001","value":"-4.476","spread":"0.113"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.449","spread":"0.036"},{"groupId":"OG001","value":"-5.373","spread":"0.070"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.635","spread":"0.212"},{"groupId":"OG001","value":"-5.473","spread":"0.068"}]}]}]},{"type":"SECONDARY","title":"Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)","description":"The table below shows actual values of log10 HCV RNA levels. From Week 4 onwards, most participants in TMC 435 150mg 12Wks PR24/48 group had plasma HCV RNA levels below the limit of detection of the HCV RNA assay.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.884","spread":"0.049"},{"groupId":"OG001","value":"5.445","spread":"0.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.889","spread":"0.041"},{"groupId":"OG001","value":"5.376","spread":"0.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.128","spread":"0.034"},{"groupId":"OG001","value":"3.838","spread":"0.130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.018","spread":"0.034"},{"groupId":"OG001","value":"2.005","spread":"0.109"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.956","spread":"0.002"},{"groupId":"OG001","value":"1.108","spread":"0.042"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.954","spread":"0.000"},{"groupId":"OG001","value":"0.995","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With On-treatment Virologic Response at All Time Points","description":"The table below shows the percentage of participants with HCV ribonucleic acid (RNA plasma levels below the limit of detection (ie, \\<25 IU/mL undetectable), the percentage of participants with a HCV RNA plasma level below the limit of quantification (ie, less than \\[\\<\\] 25 IU/mL detectable or undetectable), the percentage of participants with plasma levels of HCV RNA \\<100 IU/mL, the percentage of participants with virologic responses of a greater than or equal to 2 log10 change from baseline in plasma levels of HCV RNA.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"77.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"89.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"37.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"35.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"87.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving a Rapid Virologic Response (RVR)","description":"The table below shows the percentage of participants in each treatment group who achieved a RVR, defined as having undetectable plasma Hepatitis C virus ribonucleic acid levels after receiving 4 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving a Early Virologic Response (EVR)","description":"The table below shows the percentage of participants who achieved an EVR, defined as having a change from baseline in plasma Hepatitis C virus ribonucleic acid of greater than or equal to 2 log10 at Week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)","description":"The table below shows the percentage of participants in each treatment group who had a cEVR, defined as having undetectable plasma Hepatitis C Virus ribonucleic acid levels at Week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"27.4","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)","description":"The table below shows the percentage of participants in each treatment group who had a eRVR, defined as having undetectable plasma Hepatitis C Virus ribonucleic acid levels at Week 4 and 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4","description":"The table below shows the percentage of participants in each treatment group with \\<1 log10 HCV RNA decrease at Week 4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4","description":"The table below shows the percentage of participants in each treatment group with HCV RNA levels \\>1000 IU/mL at Week 4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"69.9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Null Response","description":"The table below shows the percentage of participants with null response, defined as \\<2 log10 reduction in Hepatitis C virus ribonucleic acid at Week 12 compared to baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Partial Response","description":"The table below shows the percentage of participants with partial response, defined as =\\>2 log10 reduction in Hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 compared to baseline, but not achieving undetectable HCV RNA while on treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Viral Breakthrough","description":"The table below shows the percentage of participants with viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached (ie, lowest value measured in between baseline and current value), or a confirmed plasma HCV RNA level of greater than 100 IU/mL in participants whose plasma HCV RNA had previously been below the limit of quantification (25 IU/mL detectable) or undetectable (\\<25 IU/mL undetectable).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Viral Relapse","description":"The table below shows the percentage of participants with viral relapse, defined as having confirmed detectable plasma level of Hepatitis C virus (HCV) ribonucleic acid (RNA) during the follow-up period in participants with undetectable plasma HCV RNA (less than 25 IU/mL undetectable) at the end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null},{"groupId":"OG001","value":"50.5","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule","description":"The table below shows the percentage of participants in the TMC435 treatment group who met the treatment duration rule (ie, having hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] levels \\<25 IU/mL detectable or undetectable at Week 4 and undetectable HCV RNA levels at Week 12) and completed treatment with PegIFNα-2a and RBV for 24 weeks. Participants in the TMC435 treatment group not meeting RGT criteria and participants in the placebo group were treated with PegIFNα-2a and RBV treatment for 48 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With On-treatment Failure","description":"The table below shows percentage of participants with on-treatment failure defined as confirmed detectable Hepatitis C virus ribonucleic acid levels at actual end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable","description":"The table below shows mean time in days to reach HCV RNA levels \\<25 IU/mL undetectable or detectable.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable","description":"The table below shows mean time in days to reach HCV RNA levels \\<25 IU/mL undetectable or detectable.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL","description":"The table below shows mean time in days to reach HCV RNA levels \\<100 IU/mL.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL","description":"The table below shows mean time in days to reach HCV RNA levels \\<1000 IU/mL.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Viral Breakthrough at Different Time Points","description":"The table below shows the percentage of participants at different time points with viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in plasma HCV ribonucleic acid (RNA) level from the lowest level reached (ie, lowest value measured in between baseline and current value), or a confirmed plasma HCV RNA level of greater than 100 IU/mL in participants whose plasma HCV RNA had previously been below the limit of quantification (25 IU/mL detectable) or undetectable (\\<25 IU/mL undetectable).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From End-of-treatment to Viral Relapse","description":"The table below shows the mean number of days to viral relapse, defined as participants having confirmed detectable plasma level of Hepatitis C Virus (HCV) ribonucleic acid (RNA) during the follow-up period in participants with undetectable plasma HCV RNA (\\<25 IU/mL undetectable) at the end of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284.09","spread":"6.56"},{"groupId":"OG001","value":"115.22","spread":"6.72"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)","description":"The percentage of participants analyzed were those with baseline ALT values out of the normal range (ie, 156 of 260 participants in the TMC435 treatment group and 84 of 133 participants in the Placebo group had ALT values at baseline that were out of the normal range.). Normalization of ALT values means that ALT values out of the normal range returned to within the normal range.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"69.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Normalization of Alanine Aminotransferase (ALT) Levels","description":"The table below shows the median time to normalization of ALT levels.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.86","spread":null},{"groupId":"OG001","value":"8.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)","description":"The table below shows mean (standard deviation) values of the area under the plasma concentration-time curve from time of administration to 24 hours (AUC 24hr) after dosing for TMC435. To calculate the mean AUC 24 for the study, AUC 24 hr values were derived for each participant at each visit and then the median of AUC value across visits for each participant was used to calculate the mean AUC 24 hr for the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60987","spread":"67577.4"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)","description":"The table below shows mean (standard deviation) of C0h values of TMC435. To calculate the mean C0h for the study, C0h values were derived for each participant at each visit and then the median of C0h values across visits for each participant was used to calculate the mean C0h for the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2081","spread":"2807.6"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of TMC435: Systemic Clearance (CL)","description":"The table below shows mean (standard deviation) of CL values of TMC435. To calculate the mean CL for the study, CL values were derived for each participant at each visit and then the median of CL values across visits for each participant was used to calculate the mean CL for the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.92","spread":"3.438"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":260},"commonTop":["Fatigue","Headache","Pruritus","Influenza like illness","Pyrexia"]}}}